Erythroid burst-promoting activity (BPA) is released from B lymphocytes in soluble (sBPA) and membrane-bound (mBPA) forms. To study intracellular processes involved in production of these physically separable factors, we measured their time course release into serum-free medium from B cells that were pulse-exposed for 5-240 min to nonmitogenic base medium or inhibitors of energy-dependent metabolism (2,4-dinitrophenol, sodium azide, and 2-deoxy-D-glucose), transcription and translation (actinomycin D and cycloheximide), replicative DNA synthesis (cytosine arabinoside), or posttranslational processing (monensin). mBPA and sBPA were initially detectable after 1 and 2 h, respectively. Maximum cumulative levels of8±0.6 and 9±1.0 U/ml, respectively, were reached after 8 h. In contrast, cumulative mBPA and sBPA levels in medium prepared from cells treated with metabolic inhibitors were reduced by up to 90%. Both surface exfoliation and mBPA expression by intact plasma membranes were diminished. Whereas pulse-exposure to cytosine arabinoside had no effect, treatment with actinomycin D or cycloheximide abolished BPA expression. Exposure to monensin reduced mBPA and sBPA levels to zero in a concentration-and time-dependent fashion. We conclude that production and release of BPA is an energy-dependent process, requiring mRNA synthesis and translation and posttranslational remodeling of the protein but not replicative DNA synthesis. (J. Clin. Invest. 1991. 87:213-220.).
Introduction
Human hematopoietic stem/progenitor cells require cytokines in sufficient concentrations for differentiation and proliferation in vitro (1) (2) (3) . Many of these factors are produced locally within the bone marrow by neighboring mononuclear cells (4, 5) . Normal and transformed B lymphocytes are one source of growth regulators that are required for lineage-specific and panspecific hematopoiesis (6) (7) (8) (9) . Although the spectrum of B cell-derived biological activities has been characterized, intracellular processes resulting in the production and release of such factors are largely undefined.
In the present study we examine the time course release of erythroid-directed growth regulatorsrinto serum-free, liquid culture medium from B lymphocytes that were pulse-treated Address reprint requests to Dr. Dainiak, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06032. Receivedfor publication 3 April 1990 and in revisedform 16 July 1990. with specific inhibitors ofcell metabolism, protein synthesis, or DNA synthesis. The results indicate that the release of soluble and membrane-associated B lymphokines is an energy-dependent process that requires active cell metabolism. Whereas mRNA synthesis, translation, and vesicular transport through the Golgi apparatus are involved in factor production and/or release, DNA synthesis is not essential for expression of these activities. Thus, erythroid growth factor synthesis and/or release involves cellular pathways that are similar to those required for endocrine hormone production (10, 11) .
Methods
Cell collection and separation. Human plateletpheresis residues were collected from healthy volunteers for 2-3 h (model CS3000, Fenwal Inc., Ashland, MA). Informed consent was obtained before pheresis in accordance with Institutional Review Board policies. Cell concentrates were immediately diluted in minimum essential medium (MEM) (Gibco Laboratories, Grand Island, NY) with 20-U preservative-free heparin per ml, layered over Ficoll-Paque (Pharmacia, Inc., Piscataway, NJ), and centrifuged at 800 g for 20 min. Light-density mononuclear cells located at the interface were removed with a Pasteur pipette, resuspended, and depleted of platelets by centrifugation over sucrose ( 12) . Platelets were removed and the washed mononuclear cells were incubated in polystyrene dishes for 60 min at 37°C to remove monocytes, and passed over a nylon wool column, as previously described (12) . B lymphocytes that were 92-96% pure by surface immunophenotyping were gently dislodged from the nylon, washed, and incubated with or without inhibitor, as described below. In some experiments, monocyte-depleted, light-density mononuclear cells were rosetted with 2-amino-ethylisothiouronium bromide-treated sheep erythrocytes to remove T lymphocytes, and B cells (2 99% pure) were separated by indirect panning with mouse anti-B4 antibody (a gift of Dr. Albert Najman, Faculte de Medicine, H6pital Saint-Antoine, Paris) as described previously (13 Transcription and translation inhibitors were tested at 10-100 ,ug/ml, and included actinomycin D (Sigma Chemical Co.), an inhibitor of messenger RNA synthesis, and cycloheximide (Sigma Chemical Co.), an antibiotic that inhibits peptidyl transferase activity ( 17) . Monensin (Sigma Chemical Co.), a carboxylic ionophore which interferes with vesicular traffic ofnewly synthesized peptides through the Golgi apparatus and terminal glycosylation ( 18) , was employed at I0-to 10-6 M as an inhibitor of posttranslational processing. To determine whether monensin alters BPA expression after its release from lymphocytes, I V or 10-8 M of the drug was incubated with CM for up to 14 h and residual activity was assayed in the CM after exhaustive dialysis against PBS (see below). Cytosine arabinoside (Sigma Chemical Co.), an analogue of 2'-deoxycytidine, was used as an inhibitor of replicative DNA synthesis at concentrations of 10-8 to 10-6 M.
Extraction of BPA from plasma membranes and shed vesicles. Plasma membranes and membrane vesicles exfoliated into CM from the surface of control and test B lymphocytes were purified, detergent treated, and assayed for extractable BPA, as previously described ( 19, 20 
Results
Kinetics of BPA release from untreated cells. Release of BPA from highly purified lymphocytes incubated in base medium was determined as a function oftime. As shown in Fig. 1 ity in CM(P) precedes that of CM(S) by -1 h (see Fig. 1 a) . The sum of activity in CM(P) and CM(S) approximates total activity present in unseparated CM (tBPA). Addition of nontoxic protease inhibitors during the conditioning process did not alter BPA levels in either unseparated CM or CM fractions (Table I) . Similar results were obtained when combinations of protease inhibitors were employed. The rate ofBPA release peaked at 3.5±0.3 U/ml per h at 4 h of incubation (see Fig. 1 b) . Peak rate of release of mBPA (2.5±0.2 U/ml per h) preceded that of sBPA release (2.4±0.3 U/ml per h), as shown in Fig. I b. Together, the data indicate that the time course release of BPA is similar to that of the release of other lymphokines (24, 25) , and is also consistent with BPA release from unseparated lymphocytes (13) .
Energy requirement for BPA production. Inhibitors of energy-dependent metabolism (0.1 mM DNP, 10 mM sodium azide, or 10 mM deoxyglucose) were preincubated with B lymphocytes that were washed and, subsequently, used as a source of BPA. As shown in Fig. 2 Fig. 2 ) was reduced to rom 14.2±0.8 U/ml at 5 min to 9.0±0.8 U/ml at 120 it is consistent with production of BPA (see tBPA re-2 h of 7.0±0.8 U/ml in Fig. 1 a) Incubation (h) sodium azide, and deoxyglucose, respectively). Moreover, expression ofmBPA per microgram ofplasma membrane or shed extracellular membrane vesicles was also reduced (Table II) . Taken together, the data suggest that growth factor localization to the plasma membrane and exfoliation from the cell surface require active cell metabolism. Level ofregulation ofBPA synthesis. To assess the level of regulation of BPA synthesis, B cells were pulse-exposed to base medium or inhibitors of transcription, translation, or DNA synthesis. As shown in Table III , even brief (5 min) treatment with actinomycin D or cycloheximide reduced the levels of mBPA and sBPA recovered in CM after 14 h of incubation to zero. tBPA, mBPA, and sBPA released into CM after 1, 2, 4, or 8 h of incubation were also undetectable in CM prepared from treated cells. At a concentration of 10 ig of cycloheximide/ml, levels of tBPA, mBPA, and sBPA were barely detectable (relative to control, P < 0.05) (data not shown). In contrast, pulse-exposure of B cells to cytosine arabinoside for as long as 120 min had no effect on the expression of sBPA or mBPA in dialyzed CM harvested after 14 h ofincubation (Table IV) . This observation is of interest since mitogens are frequently added during incubation of lymphoid cells for the preparation of cytokine-containing CM.
Intracellular processing ofBPA. Column-purified BPA migrates as a broad "band" on tightly crosslinked SDS gels, consistent with the charge heterogeneity of glycoproteins ( 19) . Therefore, we assessed the involvement of the Golgi apparatus in the processing of BPA by using monensin, an agent that interferes with transport ofproteins through this organelle. Fig.  4 shows that monensin pretreatment results in dose-dependent and time-dependent reduction in tBPA released into CM after 14 h. Whereas 10-9 M of the drug showed no effect, 10-8 M reduced activity from 12.4+0.9 to 2.1±0.6 U/ml (P < 0.05). An equal reduction in mBPA and sBPA was observed (Fig. 4 a) Highly purified B cells were incubated with nonmitogenic base medium, 0.1 mM DNP, 10 mM sodium azide, 10 mM deoxyglucose, or 1o-8 M monensin (+ inhibitors) for 120 min at 370C. They were pelleted, washed, and used to prepare intact plasma membranes (PM) and CM after a 2-, 4-, or 14-h incubation. Shed vesicles were recovered from pellets of CM. The amounts of mBPA and protein sequentially extracted with NaOH and n-octyl #-D-glucopyranoside from PM and P were measured, and specific activity was calculated. Results are recorded as mean±SE in quadruplicate experiments. In each case, the value in test PM or P is lower than that in control samples at the < 0.05 level. contrast, monensin had no effect on tBPA expression after its release into CM (Fig. 4 b) , suggesting that monensin-mediated reduction in BPA levels is due to impaired processing rather than to modification of a fully processed molecule. As shown in Table II , specific activity ofthe growth factor was reduced in both shed vesicles and intact plasma membranes derived from monensin-treated cells.
Discussion
Hematopoietic-specific growth factors are endocrines and paracrines whose primary action is to control progenitor/stem cell proliferation in a receptor-dependent fashion (2, 3, 5) . In this respect, they are similar to other polypeptide growth factors and oncogene products whose hormone-like action is initiated by receptor interaction (28) . Many of the latter regulators of cell viability and growth have been found to alter hematopoietic stem/progenitor cell proliferation, including platelet-de- B cells were pretreated for 120 min at 370C with base medium (control) or cytosine arabinoside (inhibitor) at the indicated concentrations. Cells were washed and resuspended in base medium for 14 h at 370C. CM was harvested, fractionated, and assayed for BPA, as described in Methods.
rived growth factor (29-3 1), insulin-like growth factors I and II (32) (33) (34) , transforming growth factors (35) , and a variety of "public" hormones whose actions are diverse and whose target cells are widely distributed throughout the body (36) . Peripheral blood, bone marrow, and splenic lymphocytes represent another source of hematopoietic growth factors. Here, we have examined cellular mechanisms involved in the production and release ofthe human lymphokine BPA, a factor previously purified in this laboratory (20) , and found by the investigators to be biochemically and immunologically distinct from other hematopoietic cytokines, including interleukin 3 and erythroid potentiating activity (8, 20, 37) . The results indicate that pathways utilized for BPA production are analogous to those involved in peptide hormone synthesis by cells of endocrine glands.
To examine the level of regulation of BPA synthesis/release, the effects ofvarious agents known to interfere with replicative DNA, mRNA, and protein synthesis on BPA production was determined. The results demonstrate that the transcription. inhibitor actinomycin D and the translation inhibitor cycloheximide both completely block assayable BPA production. Not only sBPA but also membrane-associated BPA was reduced (see Table III ), suggesting that the generation of either form ofthe factor requires active mRNA and protein synthesis. In contrast, DNA synthesis does not appear to be required for elaboration of these activities (see Table IV ). This result is consistent with the previous experience that, whereas lymphocyte exposure to lipopolysaccharide or plant lectins augments growth factor levels in CM, it is not essential for their production (19) . Accordingly, lymphocyte mitogens may increase growth factor synthesis similar to their selective augmentation of the level of synthesis of other cytosolic proteins (38, 39) , without requiring the cells to undergo replicative DNA synthesis, entry into S phase and ultimately, mitotic division.
Preliminary characterization of BPA shows it to be an integral membrane glycoprotein that is similar to other hematopoietic growth factors in molecular mass and charge heterogeneity (2, 3, 19, 20) . Since remodeling and terminal glycosylation of oligosaccharide units of many glycoproteins take place in the Golgi apparatus, the effects of monensin on BPA expression were assessed. Marked reductions in both total and specific activities of the factor in CM and plasma membranes prepared from monensin-treated cells (see Table II and Fig. 4 ) strongly suggest that production of bioactive BPA involves transport through and out of the Golgi complex. The importance ofposttranslational processing is further supported by the finding that enzymatic deglycosylation of column purified BPA removes > 90% of bioactivity (personal observation).
Normal and neoplastic cells shed surface membrane components (19, (40) (41) (42) . Exfoliation of plasma membrane constituents may mediate diverse cell functions, including communication with other cells within the proximal environment, selective release of lipids and proteins, activation of the blood coagulation system, and embryonic proteolysis (43) . Shedding ofgangliosides and other membrane components from the surface of neoplastic cells may be a mechanism by which these cells suppress antigen presentation (44) , alter immune effector responses (45) , and escape immune detection (46) . We have observed that membrane vesicles shed from the surface of normal lymphocytes behave as carriers of signal molecules for-hematopoietic progenitor/stem cells (12, 19 well as fluidity properties of vesicles shed from murine and human lymphocytes are distinct from those of intact lymphocyte plasma membranes (47, 48). Therefore, rather than being a random process, cell surface exfoliation may be a directed activity (48) . If true, then one would predict that surface shedding requires active cell metabolism and consumes energy. The results indicate that this is the case with regard to the release of mBPA from B lymphocytes. Both surface membrane exfoliation per se and mBPA expression by CM (P) were markedly reduced by pulse-exposure to metabolic inhibitors of cell metabolism (see Fig. 3 and Table II ). There was no apparent delay in extracellular membrane vesicle formation over the 14-h incubation used in this study, and cell viabilities immediately after drug exposure and at the time of CM harvest were similar to those of untreated cells. Interestingly, a recent report indicates that platelets which are incubated with 2-deoxyglucose and antimycin A fail to shed membrane vesicles in response to collagen or thrombin but show apparently normal vesiculation in response to complement (49) , suggesting that in some cases, active metabolism is required for platelet vesiculation as well. Several mechanisms have been thought to be involved in plasma membrane exfoliation (40) . Cell surface proteases (50, 51) and phospholipases (52) may enzymatically modify the plasma membrane, resulting in extracellular vesicle formation.
Results showing that the addition during conditioning of protease inhibitors, including leupeptin, aprotinin, TPCK, TLCK, and/or PMSF does not alter BPA levels in CM(P) (see Table I ), suggest that release of the activity in association with vesicles is not likely due to proteolysis. Nevertheless, since other surface proteases (such as the acidic and metalloproteases) were not specifically inhibited, the possibility that proteolysis may participate in mBPA release from the cell membrane has not been completely excluded.
In addition, cytoskeletal proteins may play a role in extracellular vesiculation (53, 54) . The investigators have previously reported that actin filament formation is necessary for surface exfoliation and mBPA expression by both intact lymphocyte plasma membranes and shed extracellular vesicles (54) . Accordingly, microfilament integrity may be important for mBPA localization as an integral component of the plasma membrane. Since actin polymerization is an energy-consuming process (55) , the possibility that cell metabolism is required for mBPA expression by plasma membranes was investigated. The results show that the specific activity of mBPA in extracts of intact plasma membranes is markedly reduced by metabolic inhibitors (see Table II ), suggesting that intracellular trafficking and/ or insertion of growth factor into the plasma membrane requires metabolic energy. The relationship ofsoluble and membrane-bound forms of the factor is unknown but kinetic analysis of their appearance in liquid culture medium (see Fig.  1 ) raises the possibility that sBPA may be derived from mBPA, an hypothesis that is supported by the finding that a monoclonal antibody can be used to immunoadsorb both sBPA and solubilized mBPA from solution (56) .
In summary, we report that pulse-treatment of B lymphocytes with specific inhibitors of mRNA synthesis, translation, and posttranslational modification renders the cells incapable of producing and releasing the erythropoietic growth factor BPA. Exposure to inhibitors ofenergy-dependent cell metabolism results in impaired extracellular vesiculation and reduced activity per ug membrane protein. The data suggest a model wherein BPA production by lymphocytes is similar to hormone synthesis in endocrine cells, involving transcription, translation, and processing of the growth factor. Moreover, release ofthe growth factor as an integral component ofextracellular, membrane-derived vesicles also requires cell metabolism, supporting the concept that exfoliation is a directed cell process that enables neighboring cells to signal each other.
